USD 7.85
(-0.13%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -4.15 USD | -11.86% |
2022 | -3.71 USD | -588.16% |
2021 | 0.76 USD | 135.68% |
2020 | -2.13 USD | -23.12% |
2019 | -1.73 USD | -20.98% |
2018 | -1.43 USD | -14.4% |
2017 | -1.25 USD | -71.23% |
2016 | -0.73 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | -1.02 USD | -2098.28% |
2024 Q1 | -0.05 USD | 95.7% |
2023 Q2 | -1.02 USD | 7.27% |
2023 FY | - USD | -11.86% |
2023 Q1 | -1.10 USD | -19.57% |
2023 Q3 | -0.95 USD | 6.86% |
2023 Q4 | -1.08 USD | -13.68% |
2022 Q2 | -0.90 USD | 6.25% |
2022 Q4 | -0.92 USD | -9.52% |
2022 FY | - USD | -588.16% |
2022 Q1 | -0.96 USD | -124.18% |
2022 Q3 | -0.84 USD | 6.67% |
2021 Q1 | -1.08 USD | -31.71% |
2021 FY | - USD | 135.68% |
2021 Q2 | -1.09 USD | -0.93% |
2021 Q4 | 3.97 USD | 457.66% |
2021 Q3 | -1.11 USD | -1.83% |
2020 FY | - USD | -23.12% |
2020 Q1 | -0.63 USD | -65.79% |
2020 Q2 | -0.93 USD | -47.62% |
2020 Q3 | 0.03 USD | 103.23% |
2020 Q4 | -0.82 USD | -2833.33% |
2019 Q4 | -0.38 USD | 25.49% |
2019 Q3 | -0.51 USD | 20.31% |
2019 Q2 | -0.64 USD | -56.1% |
2019 Q1 | -0.41 USD | -46.43% |
2019 FY | - USD | -20.98% |
2018 Q3 | -0.25 USD | 21.88% |
2018 FY | - USD | -14.4% |
2018 Q2 | -0.32 USD | 76.64% |
2018 Q1 | -1.37 USD | -153.7% |
2018 Q4 | -0.28 USD | -12.0% |
2017 Q1 | -0.29 USD | 0.0% |
2017 FY | - USD | -71.23% |
2017 Q4 | -0.54 USD | 42.55% |
2017 Q3 | -0.94 USD | -141.03% |
2017 Q2 | -0.39 USD | -34.48% |
2016 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
ADC Therapeutics SA | -2.94 USD | -41.156% |
Alto Neuroscience, Inc. | -1.35 USD | -207.407% |
Annovis Bio, Inc. | -6.23 USD | 33.387% |
Biohaven Pharmaceutical Holding Company Ltd. | -5.73 USD | 27.574% |
Ginkgo Bioworks Holdings, Inc. | -18.37 USD | 77.409% |
Nuvation Bio Inc. | -0.35 USD | -1085.714% |
Nuvation Bio Inc. | -0.35 USD | -1085.714% |
Zymeworks Inc. | -1.72 USD | -141.279% |